4.7 Article

Amyloid-β(1-42) alters structure and function of retinal pigmented epithelial cells

Journal

AGING CELL
Volume 8, Issue 2, Pages 162-177

Publisher

WILEY
DOI: 10.1111/j.1474-9726.2009.00456.x

Keywords

aging; degeneration; oxidative stress; retina; tight junction

Funding

  1. EVI-GenoRET [LSHG-CT-2005-512036]
  2. RETINA France
  3. Ministere de la Recherche
  4. FEdEration des Aveugles et HandicapEs Visuels de France
  5. Agence Nationale de la Recherche Scientifique (ANR)

Ask authors/readers for more resources

Age-related macular degeneration (AMD) is characterized by the formation of drusen, extracellular deposits associated with atrophy of the retinal pigmented epithelium (RPE), disturbance of the transepithelial barrier and photoreceptor death. Amyloid-beta (A beta) is present in drusen but its role during AMD remains unknown. This study investigated the in vitro and in vivo effects of the oligomeric form of A beta(1-42) - OA beta(1-42) - on RPE and found that it reduced mitochondrial redox potential and increased the production of reactive oxygen species, but did not induce apoptosis in RPE cell cultures. It also disorganized the actin cytoskeleton and halved occludin expression, markedly decreasing attachment capacity and abolishing the selectivity of RPE cell transepithelial permeability. Antioxidant pretreatment partially reversed the effects of OA beta(1-42) on mitochondrial redox potential and transepithelial permeability. Subretinally injected OA beta(1-42) induced pigmentation loss and RPE hypertrophy but not RPE cell apoptosis in C57BL/6 J mice. Rapid OA beta(1-42)-induced disorganization of cytoskeletal actin filaments was accompanied by decreased RPE expression of the tight junction proteins occludin and zonula occludens-1 and of the visual cycle proteins cellular retinaldehyde-binding protein and RPE65. The number of photoreceptors decreased by half within a few days. Our study pinpoints the role of A beta in RPE alterations and dysfunctions leading to retinal degeneration and suggests that targeting A beta may help develop selective methods for treating diseases involving retinal degeneration, such as AMD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available